4882 — Perseus Proteomics Share Price
0.000.00%
Last trade - 00:00- ¥4bn
- ¥3bn
- ¥94m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.7 | ||
| Price to Tang. Book | 2.7 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 43.71 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -66.63% | ||
| Return on Equity | -53.98% | ||
| Operating Margin | -1175.22% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 275.96 | 85.76 | 67.95 | 71.93 | 94.2 | 100,000 | n/a | -20.89% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Perseus Proteomics Inc is a Japan-based company principally engaged in the research, development, manufacture and sale of pharmaceuticals. The Company is involved in the research and development of therapeutic drugs for cancer and other diseases and related businesses. The Company is involved in the research, development, licensing, and manufacturing method establishment for commercialization in the fields of drug discovery, antibody research support, as well as antibody and reagent sales. The products include PPMX-T001, a therapeutic agent that targets glypican 3 (GPC3) present on the surface of cancer cell membranes; PPMX-T002, a therapeutic agent that targets cadherin 3 (CDH3) present on the surface of cancer cells; PPMX-T003, a therapeutic agent that targets the transferrin receptor (TfR); PPMX-T004 therapeutic agent targeting cadherin 3 (CDH3) and others.
Directors
- Takuya Yokokawa PRE (59)
- Shinichi Suzukawa EXO (66)
- Tadashi Matsuura EXO (62)
- Toshikazu Ban DRC (60)
- Nobuo Hanai IND (68)
- Tadashi Horiuchi IND (74)
- Kinichiro Kominami IND (54)
- Kazuo Miwa IND (63)
- Takashi Ohno IND (51)
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 1st, 2001
- Public Since
- June 22nd, 2021
- No. of Shareholders
- 5,171
- No. of Employees
- 24
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 12,226,853
- Address
- Park Bldg., 4-7-6, Komaba, CHUO-KU, 103-0015
- Web
- https://www.ppmx.com/
- Phone
- +81 362648268
- Auditors
- KPMG AZSA LLC
Upcoming Events for 4882
Perseus Proteomics Inc Annual Shareholders Meeting
Q1 2025 Perseus Proteomics Inc Earnings Release
Similar to 4882
ASKA Pharmaceutical Holdings Co
Tokyo Stock Exchange
Astellas Pharma
Tokyo Stock Exchange
Astena Holdings Co
Tokyo Stock Exchange
CanBas Co
Tokyo Stock Exchange
CellSeed
Tokyo Stock Exchange
FAQ
What is the Perseus Proteomics share price?
As of Today at 19:16 UTC, shares in Perseus Proteomics are trading at ¥344. This share price information is delayed by 15 minutes.
How has the Perseus Proteomics share price performed this year?
Shares in Perseus Proteomics last closed at ¥344 and the price had moved by +18.62% over the past 365 days. In terms of relative price strength the Perseus Proteomics share price has underperformed the Nikkei 225 Index by -10.29% over the past year.
What are the analyst and broker recommendations for Perseus Proteomics?
The overall consensus recommendation for Perseus Proteomics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Perseus Proteomics dividend yield?
Perseus Proteomics does not currently pay a dividend.
Does Perseus Proteomics pay a dividend?
Perseus Proteomics does not currently pay a dividend.
When does Perseus Proteomics next pay dividends?
Perseus Proteomics does not currently pay a dividend.
How do I buy Perseus Proteomics shares?
To buy shares in Perseus Proteomics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Perseus Proteomics?
As of the previous close price of ¥344, shares in Perseus Proteomics had a market capitalisation of ¥4bn.
Where are Perseus Proteomics shares listed?
Here are the trading details for Perseus Proteomics:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4882
What kind of share is Perseus Proteomics?
Based on an overall assessment of its quality, value and momentum Perseus Proteomics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Perseus Proteomics share price forecast for 2024?
The analyst consensus target price for shares in Perseus Proteomics is ¥1,000. That is 190.7% above the last closing price of ¥344.
Analysts covering Perseus Proteomics currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
What is the trend in the Perseus Proteomics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Perseus Proteomics. Over the past six months, its share price has underperformed the Nikkei 225 Index by -35.49%.
As of the last closing price of ¥344, shares in Perseus Proteomics were trading -22.38% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Perseus Proteomics PE Ratio?
The Perseus Proteomics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥344.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Perseus Proteomics?
Perseus Proteomics' management team is headed by:
- Takuya Yokokawa - PRE
- Shinichi Suzukawa - EXO
- Tadashi Matsuura - EXO
- Toshikazu Ban - DRC
- Nobuo Hanai - IND
- Tadashi Horiuchi - IND
- Kinichiro Kominami - IND
- Kazuo Miwa - IND
- Takashi Ohno - IND